Home > Haematology > EHA 2020 > Myeloid > Asciminib monotherapy in Ph+ CML: major molecular responses

Asciminib monotherapy in Ph+ CML: major molecular responses

Presented By
Prof. Timothy Hughes, University of Adelaide, Australia
Conference
EHA 2020
Trial
Phase 1
In patients with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukaemia (CML) refractive to ABL kinase inhibition, asciminib was well-tolerated and showed initial clinical activity. Prof. Timothy Hughes (University of Adelaide, Australia) explained that asciminib binds a myristoyl site of the BCR-ABL1 fusion protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from all other ABL kinase inhibitors [1]. Asciminib targets both native and mutated BCR-ABL1 fusion proteins, including the T315I-mutant fusion protein. The safety and clinical activity of asciminib in patients with Ph+ leukaemia are unknown. Patients with Ph+ chronic phase or accelerated phase CML (n=48) were enrolled in an ongoing larger phase 1 study [2]. Patients who were relapsed/refractory or intolerant to ≥2 ABL tyrosine kinase in...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on